A novel platelet-agglutinating protein (PAP) was purified -2,000-fold from the plasma of a patient with thrombotic thrombocytopenic purpura (TTP) by ammonium sulfate fractionation, DEAE-Sephacel and concanavalin A-Sepharose chromatographies. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with and without reduction, this preparation revealed a major protein band with a molecular weight of 37,000, and a minor band with a molecular weight of 32,000-34,000. After elution from the gel, only the 37,000-mol wt protein corresponding to the major band induced the platelet agglutination. When four normal plasmas and the recovery plasma from the same TTP patient were subjected to the similar purification steps, the 37,000-mol wt major band was absent. The 125I-PAP bound to the platelets in a concentration-dependent manner. The platelet agglutination induced by PAP was not inhibited by hirudin, heparin in the presence of antithrombin III, phenylmethylsulfonyl fluoride, apyrase, aspirin, or prostaglandin I2. However, it was inhibited by IgG from normal adults and from the same TTP patient after recovery.
Introduction
Thrombotic thrombocytopenic purpura (TTP)' is characterized clinically by thrombocytopenia, microangiopathic hemolytic anemia, fluctuating neurological signs, fever, and renal abnormalities (1, 2) . The pathogenesis ofthis disorder is still not known. Deposition of microthrombi, consisting of platelets and fibrin, in the small vessels has been believed to be the primary cause ofthe clinical manifestations in TTP (3, 4) . Clinical studies have shown that some patients with TTP responded successfully to plasma infusion (5) or exchange (6) . The agglutination of autologous and homologous platelets by TTP plasma has been demonstrated in this (7) and other laboratories (8) (9) (10) . This agglutinating activity was not inhibited by hirudin, heparin in the presence of antithrombin III, diisopropyl fluorophosphate, apyrase, aspirin, or prostaglandin l2 (PGI2) (11) . However, it was inhibited by human IgG or Fab fragments purified from the adult normal plasma (12) .
In this communication, we report the purification of a 37,000-mol wt platelet-agglutinating protein (PAP) from the plasma of a TTP patient. This protein is specific for TTP because it is absent in the plasma obtained from the same patient after recovery, normal subjects and patients with disseminated intravascular coagulation (DIC), or idiopathic thrombocytopenic purpura (ITP). Some properties of this protein are described.
Methods
Materials. Aspirin, heparin, hirudin, apyrase, phenylmethylsulfonyl fluoride (PMSF), and globulin-free bovine serum albumin (BSA) were obtained from Sigma Chemical Co., St. Louis, MO. Antithrombin III was purchased from KabiVitrum Diagnostica, Stockholm, Sweden; human thrombin was from Ortho Diagnostics, Inc., Raritan, NJ; aluminum hydroxide (Amphojel) was from Wyeth Laboratories, Philadelphia, PA; and human albumin (25%) was from Armour Pharmaceutical Co., Kan- kakee, IL. Reagents used in sodium dodecyl sulfate (SDS-polyacrylamide gel electrophoresis and low molecular weight protein markers (phosphorylase, BSA, ovalbumin, carbonic anhydrase, and soybean trypsin inhibitor), blot absorbent filter paper and the nitrocellulose membrane (0.45 ,m) were supplied by Bio-Rad Laboratories, Richmond, CA. DEAE Sephacel, Con A-Sepharose, and protein A-Sepharose CL-4B were obtained from Pharmacia Fine Chemicals, Uppsala, Sweden. Enzymobead reagent used in the iodination study was obtained from Bio-Rad Laboratories. PGI2 was a gift from Dr. J. Pike, Upjohn Co., Kalamazoo, MI. Carrier-free '251I-Na (specific activity 17.4 Ci/mg), and '4C-labeled molecular weight marker proteins (phosphorylase, BSA, and ovalbumin) were purchased from New England Nuclear, Boston, MA. '25I-Protein A (specific activity 47.8 AtCi/flg) was from ICN Radiochemicals, Irvine, CA. Freund's complete and incomplete adjuvants were from Difco Laboratories, Detroit, MI. All other chemicals were of analytical grade. The citrated plasma from normal subjects, patients with TTP, DIC, or ITP was prepared as described previously ( 12) .
Preparation of washed platelet suspensions. Human platelets from normal subjects or a TTP patient after recovery were isolated from freshly drawn blood using an albumin density gradient method of Walsh et al. (13) , with some modification, as described previously (1 1). The washed platelets were suspended in Tris-saline buffer, pH 7.4, containing 133 mM NaCl, 15 mM Tris-HCl, 5 mM KC1, and 1 mM MgCl2, and adjusted to a concentration of 7.5 X 108/ml. Platelet agglutination. Platelet agglutination was measured in siliconized glass cuvettes with constant stirning in a Chrono-log aggregometer. The TTP plasma or various protein fraction collected during purification ofPAP either diluted or undiluted with Tris-saline buffer in a total volume of 0.4 ml was prewarmed at 370C for 5 min. To this, 0.1 ml of washed platelet suspension containing 7.5 X 10' platelets/ml were added. The decrease in optical density caused by the platelet agglutination was recorded. To confirm further that PAP causes agglutination, 0.1 ml of platelet suspension was mixed with 0.1 ml of Tris-saline buffer, pH 7.4, containing 10 jg PAP, and incubated at 370C for 30 min without stirring.
The incubation mixture was placed on a slide with coverslip and examined under phase microscope.
SDS-polyacrylamide gel electrophoresis. Polyacrylamide gel electrophoresis in the presence of SDS was performed according to the method of Laemmli (14) Aluminum hydroxide adsorption. To 25 ml of plasma, 1/30 vol of aluminum hydroxide (undiluted) was added dropwise with stirring. The solution was incubated at 375C for 10 min. The supernatant, which contained the platelet-agglutinating activity, was recovered by centrifugation at 10,000 g for 30 min.
Fractionation with ammonium sulfate. Aluminum hydroxide adsorbed plasma was brought to 50% ammonium sulfate saturation by the addition of saturated ammonium sulfate solution (pH 7.4). The suspension was stirred at 4VC for 30 min, and the precipitate removed by centrifugation at 10,000 g for 30 min. The precipitate was dissolved in 10 ml of 10 mM Tris-HCl, pH 7.4, and dialyzed against 3 liters ofthe same buffer. After dialysis, the turbid solution was centrifuged at 10,000 g for 20 min and supernatant used for further purification.
DEAE Sephacel chromatography. The 0-50% ammonium sulfate fraction was applied onto a DEAE Sephacel column (2.3 X 9.0 cm) and equilibrated with 10 mM Tris-HCI, pH 7.4. The column was washed with the same buffer until absorbance at 280 nm became zero. It was then eluted with a 0-0.3 M NaCl linear gradient (300 ml) in the equilibration buffer, and followed by stepwise elution with 0.3 M NaCI in the same buffer. The flow rate was 20 ml/h, and 2.0-ml fractions were collected and assayed for the platelet-agglutinating activity. The fractions in the third protein peak eluted by 0.3 M NaCl in 10 mM Tris-HCl, pH 7.4, which contained the maximum platelet-agglutinating activity, were pooled, and then were concentrated by negative pressure dialysis (DEAE Sephacel fraction III).
Concanavalin A (Con A)-Sepharose chromatography. The DEAE Sephacel fraction III was dialyzed against 20 mM Tris-HCI, pH 7.4, which contained 0.5 M NaCl, I mM CaCl2, and 1 mM MnCI2 (buffer A). The dialyzed solution was loaded onto a Con A-Sepharose column (0.5 X 9 cm) equilibrated with buffer A. The column was washed with buffer A until the absorbance at 280 nm became zero. It was then eluted with a 40-ml linear gradient of a-methyl-D-glucoside (0-0.5 M) in buffer A, and stepwise with 0.5 M, 1.0 M a-methyl-D-glucoside in buffer A, and finally with 0.1 M acetate buffer, pH 4.0, containing 0.5 M NaCl. Fractions of 0.5 ml were collected at a flow rate of 10 ml/h and assayed for the platelet-agglutinating activity. Fractions in the 4th protein peak eluted with 0.1 M acetate buffer, pH 4.0, which contained 0.5 M NaCI and possessed the maximum activity, then were pooled, dialyzed against the Tris-saline buffer, pH 7.4, and concentrated by negative pressure dialysis to a volume of 1.0 ml. The dialyzed protein (designated Con A fraction IV) was stored at -70'C. Plasma from four normal donors and from the same TTP patient after recovery was processed through the same purification steps as described above.
Iodination of PAP and albumin. PAP (Con A fraction IV) was iodinated using lactoperoxidase technique, according to 49 ,500 cpm/Mg) was incubated with platelets as a control, the platelet-bound '25I-radioactivity was <500 cpm/10' platelets, i.e., there was essentially no binding of albumin to the platelets.
Effect ofplatelet inhibitors and adult human IgGfrom normal subject and TTP patient after recovery on PAP-induced platelet agglutination. Effect of certain inhibitors, such as hirudin (I U/ml), heparin in the presence of antithrombin III (I U/ml of each), PMSF (I mM), apyrase (360 Mg/ml), aspirin (200 MM), and PGI2 (60 MM) were studied on the PAP-induced platelet agglutination. The effect ofadult human IgG from normal subjects and the TTP patient after recovery, purified as described previously (12) , were also studied. Respective amounts of different inhibitors were preincubated at 370C for 5 min with 10 Mg of PAP in Trissaline buffer, pH 7.4, in a final volume of 0.4 ml. Platelet agglutination was recorded as described earlier, by the addition of0.1 ml washed platelet suspension (7.5 X 108 platelets/ml). At the same concentration, hirudin and heparin in the presence of antithrombin III completely inhibited the thrombin (I U/ml)-induced platelet agglutination; apyrase, aspirin, and PGI2 inhibited >80% of platelet agglutination induced by collagen at 3 Mg/ml in the platelet-rich plasma, as described previously (I 1). Appropriate controls without inhibitor and blanks were always included.
Preparation ofantiserum and IgGfraction against the PAP. The Con A fraction IV was subjected to a preparative SDS-polyacrylamide gel electrophoresis, and the 37,000-mol wt polypeptide was extracted from the gel using an ISCO concentrator (ISCO, Inc., Lincoln, NE). The extracted protein was free from other contaminating proteins, as analyzed by SDS-polyacrylamide gel electrophoresis. Approximately 30 Mg ofthe protein in 0.1 ml was emulsified with an equal volume of Freund's complete adjuvant and injected into four subcutaneous sites in a New Zealand rabbit. Three similar injections were subsequently given in Freund's incomplete adjuvant after a l-wk interval. The rabbit was bled from the ear vein before immunization, and twice weekly after the last injection.
The serum was separated from the clot and stored at -20'C. For the purification of the IgG fraction, 10 ml of the antiserum was brought to 50% ammonium sulfate saturation. The precipitate was recovered by centrifugation at 10,000 g for 30 min, dissolved and dialyzed against 0.1 M sodium phosphate, pH 7.4, containing 0.02% sodium azide (buffer B). The dialyzed fraction was applied to a I X 8-cm column of protein A-Sepharose CL-4B equilibrated with buffer B. Ouchterlony immunodiffusion. Immunodiffusion was carried out on glass slides coated with 1.2% agarose in 38 mM Tris-HCI and 100 mM glycine, pH 8.7, with 0.02% sodium azide. All other conditions were the same as described previously (17) .
Immunoblotting ofPAP. The immunoblotting of polypeptides was carried out according to the method of Burnette (18) with some modifications. The electrophoresis ofdifferent protein fractions was performed on a 12% SDS-polyacrylamide slab gels according to the method of Laemmli (14) . The polypeptides were transferred electrophoretically to nitrocellulose membrane. Immediately after transfer, the nitrocellulose membrane was soaked in 100 ml of 5% BSA in 154 mM NaCl, 10 mM Tris-HCl, pH 7.4 (Tris-saline), and incubated at 40°C for 1 h on a rocking platform. The membrane was then incubated with rabbit antiserum to PAP appropriately diluted with 5% BSA in Tris-saline for 2 h at room temperature and 2 h at 4°C. The membrane was then washed in 200 ml of Tris-saline containing 0.05% NP-40 for 20 min at room temperature. After washing six times, the membrane was immersed in 5% BSA in fresh Tris-saline containing 4-7 X 105 cpm of 251I-protein A/ml. The binding of protein A was allowed to take place for 2 h with rocking at room temperature. The radioactive solution was aspirated and the nitrocellulose sheet was washed with 10 mM Tris-HCI, pH 7.4, containing 0.5 M NaCI and 0.05% NP-40, for six times as described above. It was thoroughly dried with hair dryer. The sheet was exposed to Kodak X-Omat AR film (Eastman Kodak Co., Rochester, NY) at -70°C Table I shows the different steps involved in the purification. The DEAE Sephacel chromatography of 0-50% (NH4)2S04 fraction is shown in Fig. 1 . Two protein peaks with platelet-agglutinating activity were eluted from DEAE Sephacel column. The peak with the maximum agglutinating activity, eluted in 0.3 M NaCl, was selected for further purification. The platelet-agglutinating protein recovered at this step had a specific activity of 20 U/mg of protein. Fractions under this peak were pooled, concentrated, and loaded onto a Con A-Sepharose affinity column. As shown in Fig. 2 , three peaks with the plateletagglutinating activity were observed on a Con A-Sepharose chromatography. The first peak did not bind to Con A-Sepharose and appeared in the flow-through, and had some platelet-agglutinating activity, while the other two agglutinating activity peaks bound to the Con A column. The second activity peak eluted with a linear gradient of a-methyl-D-glucoside had -20% agglutinating activity. Elution of the third activity peak was achieved with 0.1 M acetate buffer, pH 4.0, containing 0.5 M NaCl. This third activity peak (Con A fraction IV) had the maximum platelet-agglutinating activity; therefore, this was selected for detailed study. The platelet-agglutinating protein in the Con A fraction IV had a specific activity of 121.0 U/mg of protein, and was purified '-2,000-fold. The purification procedure as described above has been successfully reproduced eight times.
Attempts were made to see whether this agglutinating protein is also present in the normal and TTP plasma after recovery. Therefore, the normal plasma from fourth healthy donors, as well as the TTP recovery plasma from the same patient, were subjected to the same purification steps as described above. None ofthe plasma or fractions obtained during purification contained platelet-agglutinating activity.
Polyacrylamide gel electrophoretic studies. On a 0.1% SDS-12% polyacrylamide slab gel electrophoresis with and without reduction, the Con A fraction IV obtained from TTP plasma showed a major protein band corresponding to a molecular weight of 37,000, and a minor protein band with a molecular weight of 32,000-34,000. The 37,000-mol wt major band was completely absent in both the normal and recovery plasma, as judged by SDS-polyacrylamide gel electrophoresis (Fig. 3) .
PAP-induced platelet agglutination. The PAP agglutinated the washed human platelets. As shown in Fig. 4 , the magnitude of platelet agglutination was dependent upon the amounts of PAP (Con A fraction IV) used. After the proteins were eluted from the polyacrylamide gel, only the 37,000-mol wt protein from the major band caused the platelets to agglutinate. The purified PAP not only caused the platelets of normal subjects to agglutinate, but also the platelets of the TTP patient after recovery, from whose plasma during disease this PAP was obtained (Fig. 5) . The agglutination ofplatelets by PAP was further confirmed by observing the platelet clumps under phase microscope (Fig. 6) .
Effect ofinhibitors on the PAP-induced platelet agglutination. We have studied the effect of several inhibitors such as hirudin, Figure 1 . DEAE-Sephacel chromatography of 0-50% (NH tion. The ammonium sulfate fraction (270.8 mg) after dial 10 mM Tris-HCl buffer, pH 7.4, was loaded onto a DEAE column (2.3 X 9.0 cm) preequilibrated with the same buffer. The column was first eluted with a 300-ml linear gradient of 0-0.3 M NaCI in the same buffer, and then stepwise with 0.3 M NaCI (indicated by arrows). The flow rate was 10 ml/h, and 2.0-ml fractions were collected, dialyzed against the Tris-saline buffer, pH 7.4, and assayed for platelet-agglutinating activity, which was expressed as percentage of control. The starting TTP plasma was used as the control, and the platelet agglutination induced by 0.2 ml of TTP plasma was regarded as 100%.
heparin in the presence of antithrombin III, PMSF, apyrase, aspirin, and PG12 on the PAP-induced platelet agglutination. The results are summarized in Table II Figure 2 . Con A-Sepharose chromatography of the PAP. DEAE Sephacel peak III was concentrated and dialyzed against 20 mM Tris HCI, pH 7.4, containing 0.5 M NaCl, mM each of CaCl2 and MnCl2 (buffer A). The dialyzed sample (2.7 mg) was loaded onto a Con ASepharose column (0.5 X 9 cm) equilibrated with buffer A. The column was washed with the same buffer until absorbance at 280 nm was close to zero. It was eluted first with a 40-ml linear gradient of 0-0.5 M a-methyl-D-glucoside in buffer A, stepwise with 0.5, 1.0 M a-methyl-D-glucoside, and finally with 0. M acetate buffer, pH 4.0, containing 0.5 M NaCl (indicated by arrows). Fractions of 0.5 ml were collected at a flow rate of 5 ml/h. The platelet-agglutinating activity was expressed with respect to control, as described in the legend of Figure 1 . Ac, acetate. 4 shows the gel pattern of 7 had any significant inhibitory effect on the PAP-induced platelet agglutination. However, the IgG from normal human adults as well as from the same TTP patient after recovery at a concentration of 500 ,ug/ml almost completely inhibited the agglutination.
Binding ofPAP to human platelets. To study the binding of PAP with the platelets, platelet suspensions were incubated with various concentrations of '251-labeled PAP (Con A fraction IV) for 30 min at 370C. The amount of '251I-PAP bound to the platelets was measured. As shown in Fig. 7 , the binding of '251-PAP to the platelets was concentration dependent. In the control experiment with '25I-BSA, there was almost no binding, even at a 10-fold higher concentration.
Immunodiffusion and immunoblotting studies. The antiserum procured from rabbit after immunization with PAP formed a single precipitin line against highly purified PAP (Con A fraction IV) (not shown). Using this antiserum and Western blot technique, various fractions with platelet-agglutinating activity collected in the purification steps were examined for the presence of 37,000-mol wt PAP or its derivatives. As shown in Fig. 8 , the 37,000-mol wt band was absent in the 2nd protein peak ofDEAE Sephacel chromatography (lane 2), but present in the 1st (lane 3) and 2nd (lane 4) protein peaks of Con A-Sepharose chromatography. In addition to the 37,000-mol wt protein, the antiserum also reacted with smaller molecular weight (ao 18,000-33,000) polypeptides in the 2nd peak of Con A-Sepharose chromatography. In some preparations, a 33,000-mol wt band was also seen in the first peak of same chromatography.
In order to determine whether 37,000-mol wt PAP is specific for TTP, DEAE Sephacel fractions III, prepared from the plasma of two normal subjects, five patients with TTP, two patients with DIC, and two patients with ITP, were used for the immunoblotting. It was found that the 37,000-mol wt immunoprecipitin band was present in three out of five TTP patients, but absent in the normal subjects, patients with DIC or with ITP (Fig. 9) . In two TTP patients, a low molecular weight polypeptide (Mr = 29,000) was also noted on the autoradiograph (Fig. 9, lanes 4 and 5) .
Effect ofanti-PAP IgG on the TTP plasma-induced platelet agglutination. As shown in Table III, -.
kPAP 20 Ia/ml cantly neutralized the platelet-agglutinating activity in the plasma of three out of five TTP patients. These three TTP plasmas, whose platelet-agglutinating activity was neutralized by anti-PAP IgG, were shown to contain the 37,000-mol wt polypeptide on immunoblotting. The other two, whose platelet-agglutinating activity was not neutralized by anti-PAP IgG, did not possess the 37,000-mol wt polypeptide (Fig. 9, lanes 7 and 8) .
Discussion
Thrombotic thrombocytopenic purpura is characterized pathologically by the deposition of platelet thrombi in the capillaries and arterioles (3, 4) . The agglutination ofplatelets by TTP plasma had earlier been demonstrated in this laboratory (7). In the pres-4 5 6 M I N U T E S Figure S . Agglutination by PAP of washed platelets from a normal subject and the same TTP patient after recovery, from whose plasma during disease the PAP was purified. 0.4 ml of Tris-saline containing 30 ug/ml of PAP was incubated for 5 min at 370C and added to 0.1 ml of washed platelet suspension (7.5 X 108/ml) from a normal subject (line 2) or the TTP patient (line 3). Line 1 represents the control study in which'Tris-saline buffer without PAP was added to either normal or TTP platelet suspension. ent study, we have succeeded in highly purifying a platelet-agglutinating protein from a TTP patient plasma by ammonium sulfate fractionation, DEAE Sephacel, and Con A-Sepharose chromatographies. Its tight binding to DEAE Sephacel and Con A-Sepharose suggests that the PAP is likely a highly negatively charged glycoprotein. On SDS-polyacrylamide gel electrophoresis, the Con A fraction IV containing the maximum plateletagglutinating activity showed two protein bands: a major protein band with a molecular weight of 37,000 and a minor band with a molecular weight of 32,000-34,000. Only the 37,000-mol wt protein agglutinated the platelet after extraction from the gel. The behavior of the 37,000-mol wt protein with and without reduction was the same on SDS-polyacrylamide gel, suggesting that it is composed of a single polypeptide.
The highly purified platelet-agglutinating protein not only agglutinated the platelets from normal subjects but also those from the same TTP patient after recovery. This suggests that PAP is not an isoantibody or its derivative. The magnitude of The blot was allowed to react with rabbit antiserum against the purified PAP. The formed immune precipitates on the blot were illuminated with 1251-protein A followed by autoradiography. Lane 1, purified PAP; 2, 2nd peak of DEAE-Sephacel chromatography; and 3 and 4, 1st and 2nd protein peaks of Con A-Sepharose chromatography, respectively. Position of the PAP band was indicated with a thick arrow. 5 shows the '4C-molecular weight marker proteins: phosphorylase b (97,400), BSA (69,000), and ovalbumin (46,000).
thesis (22, 23) , did not inhibit PAP-induced platelet agglutination. This indicates that PAP-induced agglutination is independent of prostaglandin biosynthesis in platelets. PGI2, which has been shown to elevate platelet cyclic AMP levels (24) and inhibit platelet aggregation and secretion by ADP, thrombin, and subendothelial surfaces (25) , failed to inhibit the platelet agglutination caused by PAP. These findings are consistent with our previous observations that thrombin inhibitors (7), nonsteroidal anti-inflammatory drugs, and PGI2 (1 1) had no inhibitory effect on TTP plasma-induced platelet agglutination. Recently it was demonstrated that a pentapeptide extracted from Microcystitis aeruginosa caused the microcircular thrombi in the lung that were composed of platelets. Heparin, aspirin, or PGI2 was also shown to be incapable of preventing the thrombi formation (26) .
We have previously reported the inhibition of TTP plasmainduced platelet agglutination by human IgG from normal adults as well as from TTP patients after recovery, but not by human IgG from normal infants or TTP patients with active disease A mixture of 0.5 ml TTP plasma and 0.1 ml Tris-saline buffer, pH 7.4, containing various amounts of anti-PAP IgG, was incubated at 370C for 2 h. After centrifugation at 48,200 g for 1 h, the plateletagglutinating activity of the supernatant was determined. (12) . Therefore, the effect of IgG from normal adults and the same TTP patient after recovery on the PAP-induced agglutination was studied. We found that IgG at a concentration of 500 Ag/ml almost completely inhibited the platelet agglutination induced by PAP. The possible mechanism of IgG inhibition on the TTP plasma-induced platelet agglutination has been discussed previously ( 12) . To evaluate whether the platelet-agglutinating activity in the other protein peaks eluted from the DEAE-Sephacel and Con A-Sepharose columns was due to the 37,000-mol wt PAP or its derivatives, Western blot method was used. Using rabbit anti-PAP antiserum in the immunoblotting, it was shown that the 37,000-mol wt polypeptide band was absent in the 2nd protein peak of DEAE Sephacel chromatography but present in both 1st and 2nd protein peaks ofCon A-Sepharose chromatography. Other than 37,000-mol wt protein band, lower molecular weight bands were also noted in the 2nd protein peak. These antigenically identical lower molecular weight proteins could be different forms or derivatives of 37,000-mol wt PAP. The presence of 37,000-mol wt PAP is likely to account at least partially for the platelet-agglutinating activity of these two protein peaks. It is not clear why the 37,000-mol wt PAP has different affinity to Con A. It could be due to the different amounts or kinds of carbohydrates on PAP, or its complex formation with other proteins. These remain to be clarified.
In contrast to the TTP plasma obtained during active disease, when plasma from four healthy normal donors and from the same TTP patient after recovery were processed in exactly the same manner as for the active TTP plasma, we noticed the 37,000-mol wt protein band on polyacrylamide gel was completely absent. Furthermore, immunoblotting demonstrated that the 37,000-mol wt protein was presently only in three out of five TTP plasma, but absent in the plasma from normal subjects and patients with DIC or ITP. That the 37,000-mol wt protein is a platelet-agglutinating protein was further confirmed by the observation that the three TTP plasmas having the 37,000-mol wt protein band reduced their platelet-agglutinating activity significantly after incubation with rabbit anti-PAP antibodies. In conclusion, the heretofore undescribed 37,000-mol wt polypeptide possessing platelet-agglutinating activity, present only in the plasma of certain cases of TTP during active disease, is likely to contribute to the development of platelet thrombi in TTP. The substances responsible for the platelet agglutination induced by various TTP plasmas appear to be heterogeneous, as suspected before (12) .
